Lung Cancer (Diagnosis)NCT07591389
Promoting Radon Testing Among Mothers of Young Children
A study testing The radon app in people with Lung Cancer (Diagnosis), run by University of North Dakota at 2 sites in United States.
Trial summary
Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer (Diagnosis)
- What is being tested?
- The radon app
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 2 sitesUnited States
- Study dates
- 10 Apr 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants are female mothers of children aged 4 and under.
- Participants own a smartphone.
- Children brought in for appointments are their biological or adoptive child.
Who cannot join
- Previous testing for radon within the past two (2) years.
- The mother's child brought in for the appointment is over 4 years of age.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Soojung Kim Interim Dean, School of Graduate Studies, PhD, MPH contact
United States2 sites, 2 recruiting
- Recruiting
University of North Dakota Center for Family Medicine, Bismarck Clinic
Bismarck, North Dakota, 58501
Senior Manager of Clinical Operations, 701-751-6753, jodi.myrvik@und.edu
- Recruiting
University of North Dakota Center for Family Medicine, Minot Clinic
Minot, North Dakota, 58701
Senior Manager of Clinical Operations, 701-751-6753, jodi.myrvik@und.edu
About this study
Official title: Promoting Radon Testing Among Mothers of Young Children: A Translational Clinical Trial
Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to test the feasibility of the radon app to promote radon testing among mothers of children aged 4 or younger when they receive a free radon test kit.
Read the detailed description
This feasibility study enrolls mothers of children under age 4 who receive a free short-term radon test kit. Participants are introduced to and given access to a smartphone radon app designed to deliver targeted education, step-by-step testing instructions, reminders, and social-sharing prompts. The study measures cognitive outcomes (radon knowledge, self-efficacy for testing, and response efficacy beliefs) before and after app exposure, and behavioral outcomes (whether the test kit is completed and returned for lab analysis, and whether participants share radon information or recommend testing to others). Data collection combines brief baseline and follow-up surveys, app usage analytics (e.g., time in app, modules completed, reminder interactions), and laboratory confirmation of returned kits. Feasibility metrics include recruitment and retention rates, app engagement, and kit return rates.
- Conditions
- Lung Cancer (Diagnosis)
- Being tested
- The radon app
- Medical subject headings
- Lung Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The radon appBehavioural
Participants will be asked to use the radon app.
| Study group | Role | What they receive |
|---|---|---|
| The radon app | Experimental | Participants will be encouraged to download the radon app and asked to use the radon app for four months where they will be exposed to mobile friendly educational content that is created from educational print brochures about radon published by EPA. Receives: Behavioral: The radon app |
What is being measured
The primary outcome is the main question the study is designed to answer.
T1 (baseline: pre-exposure survey, distribution of free radon test kit)
T1 (baseline: pre-exposure survey, distribution of free radon test kit). The pre-expsosure survey will measure: Primary endpoints: (1) Radon knowledge, 20 true/false items); (2) self-efficacy, response efficacy, and sharing intention (7-point Likert).
Measured: Initial Enrollment to 2 months after enrollment
T2 (post-exposure survey at 2 months)
T2 refers to the time point where participants will complete the post-exposure survey, which will happen two months after T1. The primary endpoints are: (1) Changes in radon knowledge from T1 to T2, as measured by the number of correct responses to a series of 20 true/false questions (e.g., "The EPA recommends that homes with 4 picocuries per liter (pCi/L) or more of radon should be fixed."); (2) Changes in self-efficacy, response efficacy, and sharing intention from T1 to T2, measured by 7-point Likert scales; (3) Radon information shared with others and recommended to others to test their houses for radon from T1 to T2. It will be measured by a series of yes/no questions. Analyses: Aim 1-directional dependent t-tests for mean changes; McNemar's test for paired proportions of sharing.
Measured: 2 months after enrollment
T3 (end of kit tracking at 4 months)
Number of radon test kits used and returned to the laboratory by participants. Directional McNemar's test for kit return proportions T1 vs T3.
Measured: 4 months after last enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start10 Apr 2026
- Primary completionAug 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of North Dakota
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of General Medical Sciences (NIGMS)
- Responsible party
- Principal investigator, Soojung Kim, University of North Dakota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07591389
- Sponsor's protocol ID
- IRB0006486
- Other IDs
- 5P20GM155890-02
- Status last verified
- May 2026
- First submitted
- 7 Apr 2026
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Promoting Radon Testing Among Mothers of Young Children: A Translational Clinical Trial
- ClinicalTrials.gov ID
- NCT07591389
- Acronym / sponsor ID
- IRB0006486
- Conditions
- Lung Cancer (Diagnosis)
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of North DakotaUniversity, hospital or other
- Collaborators
- National Institute of General Medical Sciences (NIGMS)
- Study start
- 10 Apr 2026 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to test the feasibility of the radon app to promote radon testing among mothers of children aged 4 or younger when they receive a free radon test kit.
Detailed description
This feasibility study enrolls mothers of children under age 4 who receive a free short-term radon test kit. Participants are introduced to and given access to a smartphone radon app designed to deliver targeted education, step-by-step testing instructions, reminders, and social-sharing prompts. The study measures cognitive outcomes (radon knowledge, self-efficacy for testing, and response efficacy beliefs) before and after app exposure, and behavioral outcomes (whether the test kit is completed and returned for lab analysis, and whether participants share radon information or recommend testing to others). Data collection combines brief baseline and follow-up surveys, app usage analytics (e.g., time in app, modules completed, reminder interactions), and laboratory confirmation of returned kits. Feasibility metrics include recruitment and retention rates, app engagement, and kit return rates.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The radon app | Experimental | Behavioral: The radon appParticipants will be encouraged to download the radon app and asked to use the radon app for four months where they will be exposed to mobile friendly educational content that is created from educational print brochures about radon published by EPA. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Participants are female mothers of children aged 4 and under.
- Participants own a smartphone.
- Children brought in for appointments are their biological or adoptive child.
Key exclusion criteria (2 listed)
- Previous testing for radon within the past two (2) years.
- The mother's child brought in for the appointment is over 4 years of age.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The radon appParticipants will be asked to use the radon app. | Behavioural | The radon app |
Primary outcome
T1 (baseline: pre-exposure survey, distribution of free radon test kit)
Time frame: Initial Enrollment to 2 months after enrollment
T1 (baseline: pre-exposure survey, distribution of free radon test kit). The pre-expsosure survey will measure: Primary endpoints: (1) Radon knowledge, 20 true/false items); (2) self-efficacy, response efficacy, and sharing intention (7-point Likert).
T2 (post-exposure survey at 2 months)
Time frame: 2 months after enrollment
T2 refers to the time point where participants will complete the post-exposure survey, which will happen two months after T1. The primary endpoints are: (1) Changes in radon knowledge from T1 to T2, as measured by the number of correct responses to a series of 20 true/false questions (e.g., "The EPA recommends that homes with 4 picocuries per liter (pCi/L) or more of radon should be fixed."); (2) Changes in self-efficacy, response efficacy, and sharing intention from T1 to T2, measured by 7-point Likert scales; (3) Radon information shared with others and recommended to others to test their houses for radon from T1 to T2. It will be measured by a series of yes/no questions. Analyses: Aim 1-directional dependent t-tests for mean changes; McNemar's test for paired proportions of sharing.
T3 (end of kit tracking at 4 months)
Time frame: 4 months after last enrollment
Number of radon test kits used and returned to the laboratory by participants. Directional McNemar's test for kit return proportions T1 vs T3.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer (Diagnosis)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Soojung Kim Interim Dean, School of Graduate Studies, PhD, MPH contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing The radon app in people with Lung Cancer (Diagnosis), run by University of North Dakota at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Soojung Kim Interim Dean, School of Graduate Studies, PhD, MPH (701-777-2786, soojung.kim@UND.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
T1 (baseline: pre-exposure survey, distribution of free radon test kit) (time frame: Initial Enrollment to 2 months after enrollment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.